US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
CA2198706C
(en)
*
|
1994-09-23 |
2008-07-08 |
Yi Wang |
Methods for the treatment of inflammatory joint disease
|
EP2848634A1
(de)
|
1998-02-20 |
2015-03-18 |
Genentech, Inc. |
Hemmer der komplementären Aktivierung
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
DE19913707A1
(de)
*
|
1999-03-26 |
2000-10-05 |
Privates Inst Bioserv Gmbh |
Immunadsorber zur Sepsistherapie
|
AU781446C
(en)
*
|
1999-06-29 |
2005-12-08 |
Autogen Research Pty Ltd |
Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
|
EP2026073B1
(de)
|
2000-04-29 |
2016-03-30 |
University Of Iowa Research Foundation |
Diagnostika und Therapeutika für Erkrankungen im Zusammenhang mit Makuladegeneration
|
ES2483991T3
(es)
*
|
2000-10-10 |
2014-08-08 |
Genentech, Inc. |
Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II
|
US20020094332A1
(en)
*
|
2001-01-18 |
2002-07-18 |
Alexion Pharmaceuticals |
Method of prophylaxis against large myocardial infractions
|
EP1998266A3
(de)
|
2001-02-19 |
2009-02-11 |
Merck Patent GmbH |
Verfahren zur Identifizierung von T-Zell-Epitopen und Verfahren zur Herstellung von Molekülen mit verminderter Immunogenität
|
US20030109714A1
(en)
*
|
2001-03-22 |
2003-06-12 |
Neil Wishart |
Transition metal mediated process
|
JP2004536138A
(ja)
*
|
2001-07-26 |
2004-12-02 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
認識機能を改善する方法
|
CN100391537C
(zh)
|
2001-08-17 |
2008-06-04 |
建南德克公司 |
结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
|
EP1878441B1
(de)
|
2001-08-17 |
2018-01-24 |
Genentech, Inc. |
Komplement-Inhibitoren, die an C5 und C5a binden, ohne die Bildung von C5b zu hemmen
|
DK1461428T3
(da)
|
2001-12-03 |
2012-06-04 |
Alexion Pharma Inc |
Fremgangsmåde til at fremstille hybridantistoffer
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
WO2003081206A2
(en)
*
|
2002-03-18 |
2003-10-02 |
Alexion Pharmaceuticals, Inc. |
Stratification of patient populations having or suspected of having rheumatoid arthritis
|
ITMI20021527A1
(it)
|
2002-07-11 |
2004-01-12 |
Consiglio Nazionale Ricerche |
Anticorpi anti componente c5 del complemento e loro uso
|
AU2003270330B2
(en)
*
|
2002-09-06 |
2009-07-30 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component C5
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
US7361339B2
(en)
*
|
2003-01-09 |
2008-04-22 |
Alexion Pharmaceuticals, Inc. |
Methods for reducing morality associated with acute myocardial infarction
|
WO2005072380A2
(en)
*
|
2004-01-28 |
2005-08-11 |
Chauhan Anil K |
Membrane attack complexes associated with circulating immune complexes
|
US20070116710A1
(en)
*
|
2004-02-03 |
2007-05-24 |
Leonard Bell |
Methods of treating hemolytic anemia
|
US20050169921A1
(en)
*
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
PT1755674E
(pt)
*
|
2004-05-14 |
2015-02-05 |
Alexion Pharma Inc |
Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US7935790B2
(en)
*
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
US20070292421A1
(en)
*
|
2005-07-28 |
2007-12-20 |
Feinberg Bruce B |
Method for treating preeclampsia
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
HUE026423T2
(en)
|
2005-11-04 |
2016-05-30 |
Genentech Inc |
Use of complement biosynthetic pathway inhibitors for treating eye diseases
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
US20070196367A1
(en)
*
|
2006-02-22 |
2007-08-23 |
Valentin Dinu |
Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
|
JP5722524B2
(ja)
|
2006-03-02 |
2015-05-20 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体活性を抑制することによる同種移植片の生存の延長
|
HUE026496T2
(en)
|
2006-03-08 |
2016-06-28 |
Archemix Llc |
Complement-binding aptamers and anti-C5 agents for treating eye diseases
|
WO2007106585A1
(en)
|
2006-03-15 |
2007-09-20 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
WO2007127335A2
(en)
*
|
2006-04-27 |
2007-11-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
|
WO2007130031A1
(en)
*
|
2006-05-01 |
2007-11-15 |
Alexion Pharmaceuticals, Inc. |
Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
|
US7759304B2
(en)
|
2006-06-21 |
2010-07-20 |
Regents Of The University Of Colorado |
Targeting complement factor H for treatment of diseases
|
US7939636B2
(en)
*
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
BRPI0715869A2
(pt)
|
2006-09-05 |
2013-07-30 |
Alexion Pharma Inc |
mÉtodos e composiÇÕes para o tratamento de neuropatias mediadas por anticorpos
|
SI2698166T1
(sl)
*
|
2006-10-10 |
2016-02-29 |
Regenesance B.V. |
Inhibicija komplementa za izboljšano regeneracijo živcev
|
WO2008048689A2
(en)
*
|
2006-10-20 |
2008-04-24 |
Alexion Pharmaceuticals, Inc. |
Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
|
MY183804A
(en)
|
2006-11-02 |
2021-03-16 |
Genentech Inc |
Humanized anti-factor d antibodies
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
MX2009010181A
(es)
*
|
2007-03-22 |
2009-12-04 |
Novartis Ag |
Antigenos c5 y usos de los mismos.
|
EP1975184A3
(de)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serin- oder Threonin-Phosphorylationsorte
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
EP1983003A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylationsstellen und spezifische Antikörper
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP1983002A3
(de)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosinphosphorylations-Stellen und spezifische Antikörper
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
US8975377B2
(en)
*
|
2007-08-13 |
2015-03-10 |
Vasgene Therapeutics, Inc |
Cancer treatment using humanized antibodies that bind to EphB4
|
AU2008304778B9
(en)
|
2007-09-26 |
2014-05-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in CDR
|
AU2008314567B2
(en)
|
2007-10-18 |
2014-11-20 |
Cell Signaling Technology, Inc. |
Translocation and mutant ROS kinase in human non-small cell lung carcinoma
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US10000568B2
(en)
|
2008-04-10 |
2018-06-19 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting EGFR in cancer
|
EP2275443B1
(de)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
JP2011519373A
(ja)
*
|
2008-05-01 |
2011-07-07 |
コンプレクザ インコーポレイテッド |
ビニル置換脂肪酸
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
AU2014201433B2
(en)
*
|
2008-08-05 |
2016-05-26 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein C5
|
BRPI0916668B1
(pt)
*
|
2008-08-05 |
2021-12-28 |
Novartis Ag |
Anticorpo monoclonal isolado, composição farmacêutica, ácido nucleico isolado e vetor
|
EP2379066B1
(de)
|
2008-09-16 |
2014-03-26 |
Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. |
Verwendung von opioid antgonisten zur herstellung eines arzneimittels zur behandlung von degenerativen netzhauterkrankungen
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
EP2881402B1
(de)
|
2009-02-12 |
2017-05-10 |
Cell Signaling Technology, Inc. |
Expression mutanter ROS bei menschlichem Leberkrebs
|
DK3903829T3
(da)
|
2009-02-13 |
2023-06-26 |
Immunomedics Inc |
Immunkonjugater med en intracellulær spaltelig binding
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
RU2559526C2
(ru)
|
2009-02-24 |
2015-08-10 |
Алексион Фармасьютикалз, Инк. |
Антитела, содержащие терапевтические пептиды-миметики тро/еро
|
US20100248265A1
(en)
*
|
2009-02-27 |
2010-09-30 |
The Salk Institute For Biological Studies |
Compositions and methods for diagnosis and treatment of cancer
|
CA2766565A1
(en)
|
2009-06-23 |
2010-12-29 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
EP2453906A4
(de)
|
2009-07-02 |
2014-01-15 |
Musc Found For Res Dev |
Verfahren zur stimulation der leberregeneration
|
US8287865B2
(en)
|
2009-09-16 |
2012-10-16 |
Immunomedics, Inc. |
Class I anti-CEA antibodies and uses thereof
|
WO2011040894A1
(en)
*
|
2009-10-01 |
2011-04-07 |
Mustafa Nevzat Ilaç Sanayii A.Ş. |
Topical compositions of opioid antagonists and methods for treating skin conditions therewith
|
EP2496259B1
(de)
|
2009-11-05 |
2017-02-22 |
Alexion Pharmaceuticals, Inc. |
Behandlung von paroxysmaler nächtlicher hämoglobinurie
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
CN102985106A
(zh)
*
|
2010-03-01 |
2013-03-20 |
阿雷克森制药公司 |
用于治疗德戈斯病的方法和组合物
|
TWI667257B
(zh)
*
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
TR201002473A2
(tr)
|
2010-03-31 |
2011-09-21 |
Mustafa Nevzat �La� Sanay�� A.�. |
Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
|
SG185383A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
WO2011137362A1
(en)
*
|
2010-04-30 |
2011-11-03 |
Rother Russell P |
Antibodies having reduced immunogenicity in a human
|
EA201291241A1
(ru)
|
2010-05-14 |
2013-05-30 |
Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт |
Улучшенные нацеливающие на рецептор 2 (cr2) комплемента группы
|
USRE49339E1
(en)
|
2010-06-22 |
2022-12-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the C3D fragment of complement component 3
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
TW201241008A
(en)
*
|
2010-10-01 |
2012-10-16 |
Alexion Pharma Inc |
Polypeptides that bind to human complement component C5
|
US20120237975A1
(en)
|
2010-10-01 |
2012-09-20 |
Jason Schrum |
Engineered nucleic acids and methods of use thereof
|
WO2012073992A1
(ja)
|
2010-11-30 |
2012-06-07 |
中外製薬株式会社 |
複数分子の抗原に繰り返し結合する抗原結合分子
|
EP2468295A1
(de)
|
2010-12-21 |
2012-06-27 |
Affiris AG |
Impfstoffe basierend auf Komplementprotein C5a Peptide
|
KR102147548B1
(ko)
|
2011-02-25 |
2020-08-24 |
추가이 세이야쿠 가부시키가이샤 |
FcγRIIb 특이적 Fc 항체
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
EP2700653B1
(de)
|
2011-04-15 |
2019-07-24 |
SNU R&DB Foundation |
Komplex mit einem an ein cotinin-konjugat gebundenen anti-cotinin-antikörper sowie bindesubstanz dafür und verwendung davon
|
EP2723361B1
(de)
|
2011-06-22 |
2019-10-30 |
Apellis Pharmaceuticals, Inc. |
Verfahren zur behandlung chronischer erkrankungen mit komplementinhibitoren
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013047748A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
TW201326209A
(zh)
|
2011-09-30 |
2013-07-01 |
Chugai Pharmaceutical Co Ltd |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP4015005A1
(de)
|
2011-10-03 |
2022-06-22 |
ModernaTX, Inc. |
Modifizierte nukleoside, nukleotide und nukleinsäuren und ihre verwendungen
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
SG11201402666WA
(en)
|
2011-12-16 |
2014-10-30 |
Moderna Therapeutics Inc |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
MX2014007665A
(es)
|
2011-12-21 |
2015-03-05 |
Novartis Ag |
Composiciones y metodos para anticuerpos dirigidos al factor p.
|
AU2013222836B2
(en)
|
2012-02-20 |
2017-07-20 |
Swedish Orphan Biovitrum Ab (Publ) |
Polypeptides binding to human complement C5
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
AU2013243955B2
(en)
|
2012-04-02 |
2018-02-22 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
NZ781091A
(en)
|
2012-04-06 |
2022-04-29 |
Omeros Corp |
Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
|
ES2655842T3
(es)
|
2012-04-18 |
2018-02-21 |
Cell Signaling Technology, Inc. |
EGFR y ROS1 en el cáncer
|
WO2013192240A2
(en)
|
2012-06-18 |
2013-12-27 |
Omeros Corporation |
Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
|
EP3586874A1
(de)
|
2012-08-14 |
2020-01-01 |
IBC Pharmaceuticals, Inc. |
Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
AU2013302441B2
(en)
|
2012-08-17 |
2018-05-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for detecting complement activation
|
TW202237660A
(zh)
|
2012-08-24 |
2022-10-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
TW201418707A
(zh)
*
|
2012-09-21 |
2014-05-16 |
Alexion Pharma Inc |
補體組分c5拮抗劑之篩選分析
|
PT2922554T
(pt)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
JP6366111B2
(ja)
|
2012-12-13 |
2018-08-01 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
有効性の改善および毒性の減少のための、抗体およびsn−38からなるイムノコンジュゲートの投薬
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
JP6608702B2
(ja)
*
|
2013-01-31 |
2019-11-20 |
ソウル大学校産学協力団 |
補体関連疾患の予防及び治療のためのc5抗体及び方法
|
HUE034987T2
(en)
|
2013-03-14 |
2018-05-02 |
Alnylam Pharmaceuticals Inc |
C5 complementary component IRNS preparations and methods for their use
|
RU2015142815A
(ru)
|
2013-03-14 |
2017-04-12 |
Паркаш ГИЛЛ |
Лечение рака с использованием антител, связывающихся с поверхностным grp78
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
ES2768648T3
(es)
|
2013-03-29 |
2020-06-23 |
Alexion Pharma Inc |
Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
|
CN113621057A
(zh)
|
2013-04-02 |
2021-11-09 |
中外制药株式会社 |
Fc区变体
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
CN105683759B
(zh)
|
2013-08-07 |
2019-03-29 |
瑞颂医药公司 |
非典型溶血性尿毒综合征(aHUS)生物标志物蛋白
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
WO2015023972A1
(en)
*
|
2013-08-16 |
2015-02-19 |
Alexion Pharmaceuticals, Inc. |
Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
|
PT3039033T
(pt)
|
2013-08-28 |
2019-09-06 |
Affibody Ab |
Polipéptidos de ligação com um scaffold mutado
|
PL3038633T3
(pl)
|
2013-08-28 |
2021-07-19 |
Ipc Research, Llc |
Stabilne polipeptydy wiążące się z ludzkim dopełniaczem c5
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
CN105980401A
(zh)
|
2013-10-03 |
2016-09-28 |
现代治疗公司 |
编码低密度脂蛋白受体的多核苷酸
|
US20150104445A1
(en)
|
2013-10-10 |
2015-04-16 |
Viropharma Holdings Limited |
Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
|
EA201691215A1
(ru)
|
2013-12-12 |
2016-11-30 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA К КОМПОНЕНТУ КОМПЛЕМЕНТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
WO2015120130A1
(en)
|
2014-02-07 |
2015-08-13 |
Novartis Ag |
Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
|
WO2015127134A2
(en)
|
2014-02-20 |
2015-08-27 |
Allergan, Inc. |
Complement component c5 antibodies
|
MX2016010683A
(es)
|
2014-02-21 |
2017-05-11 |
Ibc Pharmaceuticals Inc |
Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
|
EP3110445A4
(de)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanisierter rfb4-anti-cd22-antikörper
|
EP3110804A4
(de)
|
2014-02-25 |
2017-11-22 |
Achillion Pharmaceuticals, Inc. |
Carbamat-, ester- und ketonverbindungen zur behandlung von komplementvermittelten erkrankungen
|
KR20230149865A
(ko)
*
|
2014-02-26 |
2023-10-27 |
알러간, 인코포레이티드 |
보체 성분 c5 항체
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
TW201623337A
(zh)
|
2014-05-01 |
2016-07-01 |
建南德克公司 |
抗-因子d抗體變異體及其用途
|
MA51519A
(fr)
|
2014-05-05 |
2020-11-11 |
Regeneron Pharma |
Animaux c5 et c3 humanisés
|
SG11201610222UA
(en)
|
2014-06-12 |
2017-01-27 |
Ra Pharmaceuticals Inc |
Modulation of complement activity
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
WO2016033382A1
(en)
*
|
2014-08-27 |
2016-03-03 |
Capnia, Inc. |
Methods for immune globulin administration
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
WO2016061066A1
(en)
|
2014-10-15 |
2016-04-21 |
Alexion Pharmaceuticals, Inc. |
Methods of replicating a large scale eculizumab production cell culture
|
JP6948942B2
(ja)
*
|
2014-10-15 |
2021-10-13 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
|
JP6778185B2
(ja)
|
2014-10-15 |
2020-10-28 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
細胞を培養する方法
|
WO2016094834A2
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
A method for treating a complement mediated disorder caused by an infectious agent in a patient
|
EP3233921B1
(de)
|
2014-12-19 |
2021-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5-antikörper und verfahren zur verwendung
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
EP3988110A1
(de)
|
2015-01-28 |
2022-04-27 |
RA Pharmaceuticals, Inc. |
Modulatoren der komplementaktivität
|
WO2016151558A1
(en)
|
2015-03-25 |
2016-09-29 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
ES2721781T3
(es)
|
2015-03-25 |
2019-08-05 |
Alexion Pharma Inc |
Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
WO2016178980A1
(en)
|
2015-05-01 |
2016-11-10 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
|
US10532087B2
(en)
|
2015-06-03 |
2020-01-14 |
Children's Hospital Medical Center |
Compositions and methods for treating neonatal biliary atresia
|
WO2016200627A1
(en)
|
2015-06-09 |
2016-12-15 |
Children's Hospital Medical Center |
Dosing algorithm for complement inhibitor
|
EP4365291A3
(de)
|
2015-06-12 |
2024-08-14 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c5-irna-zusammensetzungen und verfahren zur verwendung davon
|
ES2953441T3
(es)
|
2015-06-25 |
2023-11-13 |
Immunomedics Inc |
Combinación de anticuerpos anti-hla-dr o anti-Trop-2 con inhibidores de microtúbulos, inhibidores de parp, inhibidores de la cinasa de bruton o inhibidores de la fosfoinositida 3-cinasa mejora significativamente el resultado terapéutico en el cáncer
|
JP2018520139A
(ja)
*
|
2015-06-26 |
2018-07-26 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
|
AR105808A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos de amida para el tratamiento de trastornos médicos
|
WO2017035361A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Disubstituted compounds for the treatment of medical disorders
|
WO2017035351A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of medical disorders
|
WO2017035357A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Phosphonate compounds for treatment of medical disorders
|
EP3340983B1
(de)
|
2015-08-26 |
2023-10-04 |
Achillion Pharmaceuticals, Inc. |
Aryl, heteroaryl und heterocyclische verbindungen zur behandlung von immun- und entzündungserkrankungen
|
AR105809A1
(es)
|
2015-08-26 |
2017-11-08 |
Achillion Pharmaceuticals Inc |
Compuestos para el tratamiento de trastornos médicos
|
EP3340982B1
(de)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Verbindungen zur behandlung von immun- und entzündungserkrankungen
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
WO2017035401A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amide compounds for treatment of immune and inflammatory disorders
|
WO2017035405A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Amino compounds for treatment of immune and inflammatory disorders
|
US10385097B2
(en)
|
2015-08-26 |
2019-08-20 |
Achillion Pharmaceuticals, Inc. |
Ether compounds for treatment of medical disorders
|
WO2017044811A1
(en)
|
2015-09-11 |
2017-03-16 |
Bruce Andrien |
Recombinant glycosylated eculizumab and eculizumab variants
|
EP3349773A4
(de)
|
2015-09-14 |
2019-05-01 |
Cincinnati Children's Hospital Medical Center |
Verfahren und zusammensetzungen zur behandlung der gaucher-krankheit durch modulation des c5a-rezeptors
|
EP3359566A1
(de)
|
2015-10-07 |
2018-08-15 |
Alexion Pharmaceuticals, Inc. |
Verfahren zur behandlung altersbedingter makuladegeneration bei einem patienten
|
TW201718014A
(zh)
|
2015-10-12 |
2017-06-01 |
諾華公司 |
C5抑制劑於移植相關微血管病之用途
|
JP7221691B2
(ja)
|
2015-10-30 |
2023-02-14 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
T細胞媒介性同種移植片血管障害の増悪を抑制する方法
|
EP3368090A1
(de)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
WO2017105939A1
(en)
|
2015-12-16 |
2017-06-22 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
HUE065073T2
(hu)
|
2015-12-18 |
2024-04-28 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antitestek és alkalmazási eljárások
|
MX2018014560A
(es)
|
2016-05-27 |
2019-08-12 |
Alexion Pharma Inc |
Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
|
RU2018146778A
(ru)
|
2016-06-07 |
2020-07-09 |
Новартис Аг |
Режим дозирования антитела к c5
|
JP2019518028A
(ja)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
|
IL309975A
(en)
|
2016-06-14 |
2024-03-01 |
Regeneron Pharma |
Antibodies against C5 and their uses
|
MY187848A
(en)
*
|
2016-06-17 |
2021-10-26 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
JP7057290B2
(ja)
|
2016-06-27 |
2022-04-19 |
アキリオン ファーマシューティカルズ,インコーポレーテッド |
医学的障害を治療するためのキナゾリン及びインドール化合物
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
TWI831965B
(zh)
|
2016-08-05 |
2024-02-11 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
WO2018071624A1
(en)
|
2016-10-12 |
2018-04-19 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
EP3526248A4
(de)
|
2016-10-17 |
2020-07-08 |
Musc Foundation for Research Development |
Zusammensetzungen und verfahren zur behandlung von läsionen des zentralnervensystems
|
WO2018075758A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5 in a sample
|
WO2018075761A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5a in a sample
|
JP7128182B2
(ja)
|
2016-10-27 |
2022-08-30 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体関連障害におけるC5b-9沈着に関するアッセイ
|
US11123399B2
(en)
|
2016-12-07 |
2021-09-21 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
CR20220563A
(es)
|
2017-01-31 |
2022-12-07 |
Chugai Pharmaceutical Co Ltd |
Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
|
KR20240019857A
(ko)
|
2017-03-01 |
2024-02-14 |
아칠리온 파르마세우티칼스 인코포레이티드 |
의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
|
ES2933513T3
(es)
|
2017-03-01 |
2023-02-09 |
Achillion Pharmaceuticals Inc |
Compuestos macrocíclicos para el tratamiento de trastornos médicos
|
WO2018160891A1
(en)
|
2017-03-01 |
2018-09-07 |
Achillion Pharmaceutical, Inc. |
Pharmaceutical compounds for treatment of medical disorders
|
BR112019019595A2
(pt)
|
2017-03-23 |
2020-04-14 |
Univ Pennsylvania |
anticorpo, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, e, célula
|
WO2018183449A1
(en)
|
2017-03-31 |
2018-10-04 |
Alexion Pharmaceuticals, Inc. |
Method for simultaneous quantification of alxn1210 and eculizumab in human serum or urine
|
US10376595B2
(en)
|
2017-04-03 |
2019-08-13 |
Inflarx Gmbh |
Treatment of inflammatory diseases with inhibitors of C5a activity
|
KR20190138806A
(ko)
|
2017-04-03 |
2019-12-16 |
인플라알엑스 게엠베하 |
C5a 활성 억제제에 의한 염증 질병의 치료
|
JP2020517605A
(ja)
|
2017-04-19 |
2020-06-18 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
腎臓移植の感作されたレシピエントにおける抗体媒介性拒絶の予防における抗c5抗体の有効性
|
DK3612208T5
(da)
*
|
2017-04-21 |
2024-09-02 |
Volution Immuno Pharmaceuticals Sa |
Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
EP3630819B1
(de)
|
2017-05-22 |
2023-10-11 |
Alexion Pharmaceuticals, Inc. |
Dosierung und verabreichung von anti-c5-antikörpern zur behandlung von proteinverlust-enteropathie in patienten
|
CN111315411B
(zh)
|
2017-07-27 |
2023-02-28 |
瑞颂医药公司 |
高浓度抗c5抗体制剂
|
CN111163767A
(zh)
|
2017-08-02 |
2020-05-15 |
艾其林医药公司 |
治疗阵发性睡眠性血红蛋白尿症的治疗方案
|
CN111278857A
(zh)
|
2017-10-04 |
2020-06-12 |
亚力兄制药公司 |
抗c5抗体治疗患有膜增生性肾小球肾炎的患者的剂量和施用
|
WO2019084438A1
(en)
|
2017-10-26 |
2019-05-02 |
Alexion Pharmaceuticals, Inc. |
ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC AND UREMIC SYNDROME (AHUS)
|
US11866701B2
(en)
|
2017-11-01 |
2024-01-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
KR102551444B1
(ko)
|
2017-11-29 |
2023-07-06 |
에프. 호프만-라 로슈 아게 |
표적 간섭이 억제된 항-약물 항체 분석
|
EP3717004A4
(de)
|
2017-12-01 |
2021-12-01 |
Children's Hospital Medical Center |
Zusammensetzungen für interferon-blockade und verfahren zu deren verwendung
|
EP3724226A1
(de)
|
2017-12-13 |
2020-10-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5-antikörperkombinationen und verwendungen davon
|
CN112654394A
(zh)
*
|
2018-06-19 |
2021-04-13 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
AU2019315213B2
(en)
|
2018-08-01 |
2024-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
A pharmaceutical composition for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease
|
US20230022157A1
(en)
|
2018-08-20 |
2023-01-26 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
BR112021004263A2
(pt)
|
2018-09-06 |
2021-05-25 |
Achillion Pharmaceuticals, Inc. |
formas mórficas de danicopano
|
EP3846803A4
(de)
|
2018-09-06 |
2022-08-10 |
Achillion Pharmaceuticals, Inc. |
Makrocyclische verbindungen zur behandlung von medizinischen erkrankungen
|
WO2020058759A1
(en)
|
2018-09-17 |
2020-03-26 |
Kyoto University |
Administration of an anti-c5 agent for treatment of hepatic injury or failure
|
US20200095307A1
(en)
|
2018-09-21 |
2020-03-26 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for the treatment of neuromyelitis optica
|
JP2022502500A
(ja)
|
2018-09-25 |
2022-01-11 |
アキリオン ファーマシューティカルズ, インコーポレーテッド |
補体因子d阻害剤の形態
|
KR20210084533A
(ko)
|
2018-10-30 |
2021-07-07 |
알렉시온 파마슈티칼스, 인코포레이티드 |
발작성 야간 혈색소뇨증 (pnh)의 치료를 위한 항-c5 항체의 피하 투여량 및 투여
|
US20210388070A1
(en)
|
2018-10-30 |
2021-12-16 |
Alexion Pharmaceuticals, Inc. |
Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
|
WO2020106724A1
(en)
|
2018-11-20 |
2020-05-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
|
EP3730617A1
(de)
|
2019-04-26 |
2020-10-28 |
Silence Therapeutics GmbH |
Nukleinsäure zur hemmung der expression von c3 in einer zelle
|
CA3119234A1
(en)
|
2018-11-23 |
2020-05-28 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of c3 in a cell
|
GB2583560A
(en)
|
2018-12-11 |
2020-11-04 |
Admirx Inc |
Fusion protein constructs for complement associated disease
|
MX2021008919A
(es)
|
2019-01-25 |
2021-11-04 |
Alexion Pharma Inc |
Dosis y administracion de anticuerpos anti-c5 para el tratamiento del sindrome uremico hemolitico atipico (shua).
|
WO2020242849A1
(en)
|
2019-05-24 |
2020-12-03 |
Alexion Pharmaceuticals, Inc. |
Methods of treating vitiligo using an anti-c5 antibody
|
WO2021019033A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
|
AU2020322165A1
(en)
|
2019-07-31 |
2022-01-06 |
F. Hoffmann-La Roche Ag |
Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
|
WO2021026160A1
(en)
|
2019-08-05 |
2021-02-11 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis with eculizumab
|
WO2021037941A1
(en)
|
2019-08-27 |
2021-03-04 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of c3 in a cell
|
BR112022007540A2
(pt)
|
2019-10-22 |
2022-07-12 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente complementar c3 e métodos de uso das mesmas
|
JP2023507852A
(ja)
|
2019-12-23 |
2023-02-27 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
抗c5抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
EP4114947A1
(de)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
|
AU2020438234A1
(en)
|
2020-03-27 |
2022-09-29 |
Inflarx Gmbh |
Inhibitors of C5a for the treatment of corona virus infection
|
US20230416344A1
(en)
|
2020-04-16 |
2023-12-28 |
Alexion Pharmaceuticals, Inc. |
Methods for treating a complement mediated disorder caused by viruses
|
KR20230017789A
(ko)
|
2020-04-30 |
2023-02-06 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
|
US20230172930A1
(en)
|
2020-05-12 |
2023-06-08 |
Alexion Pharmaceuticals, Inc. |
Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
|
US20230235080A1
(en)
|
2020-06-03 |
2023-07-27 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
KR20230017308A
(ko)
|
2020-06-16 |
2023-02-03 |
에프. 호프만-라 로슈 아게 |
샘플에서 항체의 유리 항원 측정 방법
|
US20230303670A1
(en)
|
2020-06-24 |
2023-09-28 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
|
US20230256114A1
(en)
|
2020-07-07 |
2023-08-17 |
Bionecure Therapeutics, Inc. |
Novel maytansinoids as adc payloads and their use for the treatment of cancer
|
KR20230038773A
(ko)
*
|
2020-07-15 |
2023-03-21 |
바이오션, 인코포레이티드 |
C5에 결합하는 항체 및 이의 용도
|
EP4274896A1
(de)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2024504366A
(ja)
|
2021-01-22 |
2024-01-31 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
抗c5抗体を使用して補体媒介血栓性微小血管障害症を治療する方法
|
EP4281484A1
(de)
|
2021-01-22 |
2023-11-29 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2-konstrukte und verwendungen davon
|
EP4342497A1
(de)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antikörper mit reduzierter bindungsaffinität für antigen
|
CA3220629A1
(en)
|
2021-05-28 |
2022-12-01 |
Tobin J. CAMMETT |
Methods for detecting cm-tma biomarkers
|
WO2023023220A1
(en)
|
2021-08-20 |
2023-02-23 |
Alexion Pharmaceuticals, Inc. |
Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
|
EP4396346A1
(de)
|
2021-09-02 |
2024-07-10 |
Silence Therapeutics GmbH |
Nukleinsäuren zur hemmung der expression des komplementfaktors b (cfb) in einer zelle
|
WO2023044048A1
(en)
|
2021-09-17 |
2023-03-23 |
Novartis Ag |
Methods for prevention of graft rejection in xenotransplantation
|
EP4401742A2
(de)
|
2021-09-17 |
2024-07-24 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen und verfahren zur dämpfung der komplementkomponente 3 (c3)
|
AU2022378567A1
(en)
|
2021-10-29 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
KR20230105972A
(ko)
|
2022-01-05 |
2023-07-12 |
주식회사 카나프테라퓨틱스 |
혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
|
CN116712390B
(zh)
*
|
2023-08-04 |
2023-11-14 |
上海览屹医药科技有限公司 |
一种高浓度高稳定性的抗体制剂及其制备方法
|